N-((2R,3R,E)-1,3-Dihydroxyoctadec-4-en-2-yl)-6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)hexanamide

Catalog No. :
ACSCFZ865
CAS No. :
114301-95-0
Molecular Formula :
C30H49N5O6
Molecular Weight :
575.75

IUPAC Name:N-((2R,3R,E)-1,3-dihydroxyoctadec-4-en-2-yl)-6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)hexanamide

N-((2R,3R,E)-1,3-Dihydroxyoctadec-4-en-2-yl)-6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)hexanamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN-((2R,3R,E)-1,3-Dihydroxyoctadec-4-en-2-yl)-6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)hexanamide
IUPAC NameN-((2R,3R,E)-1,3-dihydroxyoctadec-4-en-2-yl)-6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)hexanamide
Molecular FormulaC30H49N5O6
Molecular Weight575.75
SMILESO=C(N[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)CO)CCCCCNC1=CC=C([N+]([O-])=O)C2=NON=C21
InChI KeyHZIRBXILQRLFIK-DPGCSIDFSA-N
SynonymN-(1,3-DIHYDROXYOCTADECAN-2-YL)-6-[(7-NITRO-2,1,3-BENZOXADIAZOL-4-YL)AMINO]HEXANAMIDE | N-(1,3-dihydroxyoctadecan-2-yl)-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide | C-6 NBD-dihydro-Ceramide | J-003078 | DTXSID90693945
CAS No.114301-95-0
PubChem CID53393951

Synthetic Route by SureRoute

1. ACSCFZ865 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACJSFV723 route compound structure diagram
    ACJSFV72310199-89-0 In Stock
  4. Then
  5. ACSCFZ865 route product structure diagram
    ACSCFZ865114301-95-0
Inquiry

2. ACSCFZ865 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACSCFZ865 route product structure diagram
    ACSCFZ865114301-95-0
Inquiry

Comments (0)